European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Adriaenssens, NielsCoenen, Samuel
Muller, Arno
Vankerckhoven, Vanessa
Goossens, Herman
Kristinsson, KG
ESAC Project Group
Issue Date
2010-04
Metadata
Show full item recordCitation
J. Antimicrob. Chemother. 2010;65(4):769-74Abstract
OBJECTIVES: To assess the total outpatient systemic antimycotic and antifungal use in Europe, and to identify the antimycotic and antifungal substances most commonly used. METHODS: Within ESAC (www.esac.ua.ac.be), using the anatomical therapeutic chemical (ATC) and defined daily dose (DDD) classification, data on outpatient use of all 14 antimycotics (12) and antifungals (2) for systemic use (ATC J02 and D01B, respectively), aggregated at the level of the active substance, were collected for 2007. Use was expressed in DDD (WHO ATC/DDD, version 2008) per 1000 inhabitants per day (DID). Only countries for which data on both J02 and D01B use were available were included in the analysis. RESULTS: In 20 European countries (data for Cyprus and Estonia include hospital use), total outpatient systemic antimycotic and antifungal use varied by a factor of 6.7 between the country with the highest (3.03 DID in Belgium) and the country with the lowest (0.45 in Croatia) use. Terbinafine, ketoconazole, itraconazole and fluconazole represented >94% of the total outpatient antimycotic and antifungal use in all countries. Terbinafine use represented >50% of the total systemic antimycotic and antifungal use in 16 out of 20 countries (not in Croatia, Italy, Luxembourg and Bulgaria). CONCLUSIONS: We present for the first time a standardized and validated data set of outpatient systemic antimycotic and antifungal use in Europe. Our study demonstrates a variation of antimycotic and antifungal use in Europe, as striking as that of antibiotic use. The ESAC data facilitate the auditing of antimycotic and antifungal prescribing, and the evaluation of the implementation of guidelines and public health policies to promote their judicious use.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldAdditional Links
http://dx.doi.org/10.1093/jac/dkq023Rights
Archived with thanks to The Journal of antimicrobial chemotherapyae974a485f413a2113503eed53cd6c53
10.1093/jac/dkq023
Scopus Count
Collections
Related articles
- European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe.
- Authors: Adriaenssens N, Coenen S, Kroes AC, Versporten A, Vankerckhoven V, Muller A, Blix HS, Goossens H, ESAC Project Group.
- Issue date: 2011 Aug
- Outpatient systemic antimycotic and antifungal use in Europe: new outcome measure provides new insight.
- Authors: Adriaenssens N, Coenen S, Versporten A, Goossens H
- Issue date: 2013 Nov
- European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe.
- Authors: Coenen S, Muller A, Adriaenssens N, Vankerckhoven V, Hendrickx E, Goossens H, ESAC Project Group.
- Issue date: 2009 Jul
- European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe.
- Authors: Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, Suetens C, Goossens H, ESAC Project Group.
- Issue date: 2006 Aug
- European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997-2009).
- Authors: Adriaenssens N, Coenen S, Versporten A, Muller A, Minalu G, Faes C, Vankerckhoven V, Aerts M, Hens N, Molenberghs G, Goossens H, ESAC Project Group.
- Issue date: 2011 Dec